Harvard Apparatus Regenerative Technology Inc. (HRGN)
OTCMKTS · Delayed Price · Currency is USD
1.810
-0.041 (-2.22%)
Oct 27, 2025, 12:24 PM EDT
HRGN Revenue
Harvard Apparatus Regenerative Technology had revenue of $317.00K in the quarter ending June 30, 2025, with 466.07% growth. This brings the company's revenue in the last twelve months to $679.00K, up 214.35% year-over-year. In the year 2024, Harvard Apparatus Regenerative Technology had annual revenue of $430.00K with 317.48% growth.
Revenue (ttm)
679.00K
Revenue Growth
+214.35%
P/S Ratio
46.80
Revenue / Employee
84.88K
Employees
8
Market Cap
31.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 430.00K | 327.00K | 317.48% |
| Dec 31, 2023 | 103.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
Harvard Apparatus Regenerative Technology News
- 1 year ago - Harvard Apparatus Regenerative Technology Announces Strategic Collaboration with Children's Hospital Capital institute of Pediatrics in Beijing, China to Advance Treatment for Esophageal Atresia - GlobeNewsWire
- 1 year ago - Harvard Apparatus Regenerative Technology Appoints Mao Zhang to Board of Directors - GlobeNewsWire
- 1 year ago - Harvard Apparatus Regenerative Technology Announces $5 Million Financing to Continue Clinical Trial - GlobeNewsWire
- 1 year ago - Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 1 year ago - Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 years ago - Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy - GlobeNewsWire
- 2 years ago - Harvard Apparatus Regenerative Technology and Renowned Professor/Physician Establish a Collaboration to Repair and Regenerate the Uterus - GlobeNewsWire
- 2 years ago - Harvard Apparatus Regenerative Technology Reports Third Quarter 2023 Financial Results - GlobeNewsWire